Sign in
Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Journal article   Open access  Peer reviewed

Tackling Resistance to Cancer Immunotherapy: What Do We Know?

Soehartati A Gondhowiardjo, Handoko, Vito Filbert Jayalie, Riyan Apriantoni, Andreas Ronald Barata, Fajar Senoaji, Igaa Jayanthi Wulan Utami, Ferdinand Maubere, Endang Nuryadi and Angela Giselvania
Molecules (Basel, Switzerland), Vol.25(18), p.4096
08/09/2020
PMCID: 7570938
PMID: 32911646

Abstract

Animals Antigen Presentation - immunology Antigens, Neoplasm - immunology Chemotaxis, Leukocyte - genetics Chemotaxis, Leukocyte - immunology Combined Modality Therapy Drug Resistance, Neoplasm - genetics Drug Resistance, Neoplasm - immunology HLA Antigens - genetics HLA Antigens - immunology Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy - adverse effects Immunotherapy - methods Lymphocyte Activation - genetics Lymphocyte Activation - immunology Neoplasms - genetics Neoplasms - immunology Neoplasms - metabolism Neoplasms - therapy T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism Treatment Outcome Tumor Escape - drug effects Tumor Escape - genetics Tumor Escape - immunology Tumor Microenvironment - drug effects Tumor Microenvironment - genetics Tumor Microenvironment - immunology
url
https://doi.org/10.3390/molecules25184096View
Published (Version of record) Open

Metrics

1 Record Views

Details